Exenatide for Smoking Cessation and Prevention of Weight Gain

Phase 2 Completed 140 enrolled The University of Texas Health Science Center, Houston

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if exenatide improves end-of-treatment smoking abstinence rates and to determine if exenatide mitigates post-cessation weight gain.

Timeline

Start: 2022-12-07
Primary completion: 2025-11-07
Completion: 2026-03-10

Publications

Herman RJ, Schmidt HD. Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence. Physiol Behav. 2024 Jul 1;281:114565. doi: 10.1016/j.physbeh.2024.114565. Epub 2024 Apr 23.
Yammine L, Verrico CD, Versace F, Webber HE, Suchting R, Weaver MF, Kosten TR, Alibhai H, Cinciripini PM, Lane SD, Schmitz JM. Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial. BMJ Open. 2023 Jun 14;13(6):e072707. doi: 10.1136/bmjopen-2023-072707.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Exenatide	Peptide	2 mg	Subcutaneous
Comparator	Nicotine patch	Unknown	14 mg	Other
Comparator	Nicotine patch	Unknown	21 mg	Other

Indications

No indication recorded.